EC approves Alunbrig for ALK+ non-small cell lung cancer

The European Commission granted marketing authorization for Alunbrig (brigatinib) as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.

According to the drug’s developer, Japanese drug major Takeda Pharmeutical (TYO: 4502), the EC’s approval of Alunbrig is an important advancement for European patients with ALK+ NSCLC, a life-threatening disease impacting around 40,000 patients worldwide each year. People living with this particular form of lung cancer are often younger – with little to no smoking history – and in the middle of their lives, raising their children and growing their careers. Establishing treatment options that can help delay disease progression is of the utmost importance for these patients.

Blockbuster potential